Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence

Pemetrexed and erlotinib represent novel agents for the treatment of non-small cell lung cancer (NSCLC). The role of sequential treatment in NSCLC has not been elucidated yet. We compared the efficacy of second-line pemetrexed followed by third-line erlotinib (P-E) to treatment with the reverse sequ...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2013-08, Vol.33 (8), p.3397-3402
Main Authors: Fiala, Ondrej, Pesek, Milos, Finek, Jindrich, Benesova, Lucie, Bortlicek, Zbynek, Minarik, Marek
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - genetics
Adenocarcinoma - pathology
Adenocarcinoma of Lung
Adult
Aged
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Disease-Free Survival
ErbB Receptors - genetics
Erlotinib Hydrochloride
Female
Glutamates - therapeutic use
Guanine - analogs & derivatives
Guanine - therapeutic use
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Male
Middle Aged
Neoplasm Staging
Pemetrexed
Quinazolines - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pemetrexed and erlotinib represent novel agents for the treatment of non-small cell lung cancer (NSCLC). The role of sequential treatment in NSCLC has not been elucidated yet. We compared the efficacy of second-line pemetrexed followed by third-line erlotinib (P-E) to treatment with the reverse sequence (E-P). We analyzed data of 57 patients with advanced-stage (IIIB/IV) lung adenocarcinoma harboring wild-type epidermal growth factor receptor (EGFR) gene; 31 patients were treated with P-E and 26 patients with the E-P sequence. The median progression-free survival (PFS) for patients treated with P-E was 3.6 months vs. 7.8 months for patients treated with E-P (p=0.029). The median overall survival (OS) for patients treated with P-E was 7.9 months vs. 26.3 months for patients treated with E-P (p=0.006). The results proved a significant improvement of both PFS and OS for patients treated with the E-P sequence as compared to the P-E sequence.
ISSN:0250-7005
1791-7530